Business
MTVA: New Data for Vanoglipel (DA-1241) Presented at AASLD…
By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update New Data from Phase 2a Trial of Vanoglipel (DA-1241) Presented at The Liver Meeting 2025 In November 2025, MetaVia, Inc. (NASDAQ:MTVA) announced new data from the Phase 2a clinical trial of vanoglipel (DA-1241) was presented in a poster session at the American Association for the Study of Liver Diseases (AASLD) The
About this update from Metavia Inc.
[{"type":"text","content":"By David Bautz, PhD","length":19,"tagName":"p"},{"type":"text","content":"NASDAQ:MTVA","length":11,"tagName":"p"},{"type":"text","content":"READ THE FULL MTVA RESEARCH REPORT","length":34,"tagName":"p"},{"type":"text","content":"Business Update","length":15,"tagName":"p"},{"type":"text","content":"New Data from Phase 2a Trial of Vanoglipel (DA-1241) Presented at The Liver Meeting 2025","length":88,"tagName":"p"},{"type":"text","content":"In November 2025, MetaVia, Inc. (NASDAQ:MTVA) announced new data from the Phase 2a clinical trial of vanoglipel (DA-1241) was presented in a poster session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025. A copy of the poster can be found here.","length":288,"tagName":"p"},{"type":"text","content":"Vanoglipel is a potent and selective agonist for G protein-coupled receptor 119 (GPR119). GPR119 is a G protein-coupled receptor (GPCR) that is predominantly expressed in the pancreas, liver, and gastrointestinal tract. It is activated by a large number of naturally occurring lipid molecules and elicits physiological responses through binding to G proteins that activate adenylate cyclase and cyclic AMP signaling (Hassing et al., 2016). GPR119 activation leads to glucose-dependent insulin release from the pancreas and intestinal secretion of incretins, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) (Chu et al., 2008), while also suppressing food intake to reduce body weight gain (Overton et al., 2006).","length":756,"tagName":"p"},{"type":"text","content":"The Phase 2 study enrolled a total of 109 subjects with presumed metabolic dysfunction-associated steatohepatitis (MASH) and qualifying baseline alanine aminotransferase (ALT). Subjects were randomized to receive placebo, vanoglipel 50 mg, vanoglipel 100 mg alone, or vanoglipel 100 mg with a DPP4 inhibitor in a 2:1:2:2 ration once daily for 16 weeks (NCT06054815).","length":366,"tagName":"p"},{"type":"text","content":"Following 16 weeks of treatment in a subgroup of subjects with baseline ALT levels between 40 and 200 U/L, vanoglipel significantly decreased plasma ALT, as shown in the following figure. The decrease in ALT was not enhanced in the combination group.","length":250,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":""...